Antihypertensive Treatment Prolongs Tissue Plasminogen Activator Door-to-Treatment Time
2012
Background and Purpose—Identifying modifiable tissue plasminogen activator treatment delays may improve stroke outcomes. We hypothesized that prethrombolytic antihypertensive treatment (AHT) may prolong door-to-treatment time (DTT). Methods—We performed an analysis of consecutive tissue plasminogen activator–treated patients at 24 randomly selected community hospitals in the Increasing Stroke Treatment through Interventional Behavior Change Tactics (INSTINCT) trial between 2007 and 2010. DTT among stroke patients who received prethrombolytic AHT were compared with those who did not receive prethrombolytic AHT. We then calculated a propensity score for the probability of receiving prethrombolytic AHT using logistic regression with demographics, stroke risk factors, home medications, stroke severity (National Institutes of Health Stroke Scale), onset-to-door time, admission glucose, pretreatment blood pressure, emergency medical service transport, and location at time of stroke as independent variables. A p...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
9
References
0
Citations
NaN
KQI